Serum alpha-2-macroglobulin, antitrypsin and antichymotrypsin activities in patients receiving treatment with cyclosporine

Cyclosporine has been reported to function as an inhibitor of the chymotrypsin like activity of proteasome. We hypothesized that the administration of an exogenous proteinase inhibitor may affect the activities of the naturally occurring serum anti proteinases. The aim of this study was to observe the pattern of alteration of serum alpha 2 macroglobulin (AMG), alpha 1- antitrypsin (AT) and alpha 1-antichymotrypsin (ACT) activities in renal transplant patients receiving the immunosuppressive drug, cyclosporine. Patients (97) who had received a single renal allograft were inducted into the study. Subjects were on a twice-daily dosage of cyclosporine capsules. Trough (Co) and two-hour post dose (C 2) cyclosporine levels were regularly estimated and all patients had stable creatinine levels. In 5 newly transplanted patients, antiproteinase activities were estimated weekly over a 4-week period as their cyclosporine doses were gradually tapered. Average serum activities of ACT and AMG in the transplant group were significantly less than in the control group (p<0.002 and p<0.003 respectively). AT and ACT activities fell gradually over 4 weeks. AMG activities showed a biphasic pattern, initially falling by almost 50% in the second week, increasing marginally in the third week and decreasing to less than 50% of the activities observed in the first week. Serum antiproteinase activities of serum alpha 2 macroglobulin (AMG), alpha 1-antitrypsin (AT) and alpha 1-antichymotrypsin (ACT) were found to be altered in renal transplant patients receiving cyclosporine.